Subgroups
|
No. of cases/no. of controls
|
aAdjusted model
|
P for interaction
|
---|
Selenium ≥ 94.1 ng/mL
|
Selenium < 94.1 ng/mL
|
OR (95% CI)
|
---|
Age, years
| | | |
0.288
|
< 70
|
98/110
|
173/161
|
0.73 (0.50, 1.08)
| |
≥ 70
|
99/135
|
251/215
|
0.54 (0.38, 0.76)
| |
Body mass index, kg/m2
| | | |
0.067
|
< 24
|
44/89
|
151/152
|
0.39 (0.24, 0.63)
| |
≥ 24
|
153/156
|
273/224
|
0.75 (0.55, 1.02)
| |
Current smoking
| | | |
0.739
|
No
|
95/136
|
233/231
|
0.72 (0.51, 1.01)
| |
Yes
|
102/109
|
191/145
|
0.54 (0.36, 0.80)
| |
Current alcohol drinking
| | | |
0.230
|
No
|
98/106
|
232/207
|
0.74 (0.51, 1.06)
| |
Yes
|
99/139
|
192/169
|
0.53 (0.37, 0.77)
| |
SBP, mmHg
| | | |
0.759
|
< 140
|
46/92
|
124/156
|
0.60 (0.38, 0.96)
| |
≥ 140
|
151/153
|
300/220
|
0.64 (0.47, 0.88)
| |
Glucose, mmol/L
| | | |
0.898
|
< 6.1
|
108/168
|
274/284
|
0.66 (0.48, 0.90)
| |
≥ 6.1 or diabetesb
|
89/77
|
150/92
|
0.66 (0.42, 1.02)
| |
TC, mmol/L
| | | |
0.402
|
< 5.8
|
95/107
|
262/236
|
0.77 (0.54, 1.10)
| |
≥ 5.8
|
102/138
|
162/140
|
0.53 (0.36, 0.78)
| |
TG, mmol/L
| | | |
0.611
|
< 1.2
|
115/160
|
246/255
|
0.71 (0.52, 0.98)
| |
≥ 1.2
|
82/85
|
178/121
|
0.55 (0.36, 0.84)
| |
eGFR, mL/min/1.73 m2
| | | |
0.753
|
< 90
|
64/68
|
173/141
|
0.71 (0.45, 1.10)
| |
≥ 90
|
133/177
|
251/235
|
0.61 (0.45, 0.83)
| |
tHcy, μmol/L
| | | |
0.117
|
< 12.5
|
89/105
|
129/142
|
0.81 (0.54, 1.22)
| |
≥ 12.5
|
108/140
|
293/234
|
0.55 (0.39, 0.76)
| |
Vitamin E, μg/mL
| | | |
0.007
|
< 13.5
|
117/132
|
270/277
|
0.85 (0.62, 1.17)
| |
≥ 13.5
|
80/113
|
154/99
|
0.39 (0.25, 0.60)
| |
- Abbreviations: TC, total cholesterol, T tertile, OR odds ratio, CI confidence interval
- aORs of first total stroke in relation to serum selenium levels were calculated using multivariate logistic regression models. Each subgroup analysis was adjusted, if not stratified, for age, BMI, baseline SBP, baseline DBP, smoking status, alcohol consumption, labor intensity, baseline total homocysteine, vitamin E, fasting glucose, estimated glomerular filtration rate (eGFR), anti-platelet drugs, lipoprotein-lowering drugs, glucose-lowering drugs, anti-hypertensive drugs, self-reported hypertension, self-reported diabetes, self-reported atrial fibrillation, and self-reported hyperlipidemia
- bDiabetes was defined as a self-reported history of diabetes mellitus, use of anti-diabetic medications, or fasting glucose ≥ 7.0 mmol/L